Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

The Drone Revolution's Dependence on Chinese Rare Earth Processing - OilPrice.com Market Commentary

View original at finance.yahoo.com
The Drone Revolution's Dependence on Chinese Rare Earth Processing - OilPrice.com Market Commentary NEW YORK, March 11, 2026 /PRNewswire/ -- Ukraine produced 1.2 million drones in 2024 alone…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Europe's stockpile of processed rare earths is also zero

    60% confidence

  • America doesn't have a rare earth problem; it has a processing problem

    60% confidence

  • United States currently maintains zero strategic stockpile of processed rare earths

    60% confidence

  • Virtually every magnet in Ukrainian drones used in 2024 was manufactured in China

    60% confidence

  • 1% reliance on China is 100% reliance on China

    60% confidence

  • There's nothing rare about rare earths except the processing and separating

    60% confidence

  • China controls approximately 90-95% of global rare earth processing

    60% confidence

  • No other company in North America has what REalloys has built: a proven, commercial-scale heavy rare earth supply chain

    60% confidence

  • Companies that get qualified into defense programs now might own these supply chains for decades

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
The Drone Revolution's Dependence on Chinese Rare Earth Processing - OilPrice.com Market Commentary — Source | Via News | Via News